Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
Professor of Medicine, Johns Hopkins University School of Medicine; Clinical Director, Division of Infectious Diseases, Johns Hopkins Hospital, Baltimore, Maryland
Disclosure: Paul G. Auwaerter, MD, has disclosed the following relevant financial relationships: Served as a director, officer, partner, employee, advisor, consultant, or trustee for: Infectious Diseases Society of America (volunteer) Board of Directors; US Food and Drug Administration Received a research grant from: Cerexa Received income in an amount equal to or greater than $250 from: Medicolegal expert (various)
Comments
Commenting is limited to medical professionals. To comment please Log-in.
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
COMMENTARY
Paxlovid Rebound: What Is Happening?
Paul G. Auwaerter, MD
DisclosuresMay 13, 2022
Join the Top Medical Resource for Physicians Today. Free Membership!
Tables
Authors and Disclosures
Authors and Disclosures
Author(s)
Paul G. Auwaerter, MD
Professor of Medicine, Johns Hopkins University School of Medicine; Clinical Director, Division of Infectious Diseases, Johns Hopkins Hospital, Baltimore, Maryland
Disclosure: Paul G. Auwaerter, MD, has disclosed the following relevant financial relationships:
Served as a director, officer, partner, employee, advisor, consultant, or trustee for: Infectious Diseases Society of America (volunteer) Board of Directors; US Food and Drug Administration
Received a research grant from: Cerexa
Received income in an amount equal to or greater than $250 from: Medicolegal expert (various)